Eli Lilly
on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving way for its entrance into the market.
The pill’s weight loss was 11.2% when analyzing all patients regardless of discontinuations.
Shares of the company fell more than 13% in premarket trading on Thursday.
The data comes under what some Wall Street analysts were expecting for Eli Lilly’s oral GLP-1, with hopes for weight loss of around 15%. Some doctors said the results appear to be comparable to, but overall slightly lower, the level of weight loss seen with Novo Nordisk
